期刊文献+

2-羟丙基-β-环糊精对羟基喜树碱的增溶及稳定作用研究 被引量:6

Evaluation of 2-Hydroxypropyl-β-Cyclodextrin as Solubilizing/Stabilizing Agent for Hydroxycamptothecin
原文传递
导出
摘要 目的:考察不同pH条件下2-羟丙基-β-环糊精(HPCD)对羟基喜树碱(HCPT)的增溶作用以及HCPT内酯环开闭环平衡的影响。方法:运用相溶解度法进行增溶试验,采用高效液相色谱法分别测定HCPT内酯环形式与开环羧酸盐形式药物浓度,考察不同量的HPCD对HCPT内酯环开闭环转化pH平衡点。结果:随着HPCD浓度增加,HCPT的溶解度增加;包合物表观稳定常数随pH上升而下降;HPCD浓度在0%、10%、25%时,HCPT开闭环pH平衡点分别为6.5、7.0、7.3。结论:HPCD可以提高HCPT的溶解度,对HCPT内酯环有稳定作用。 OBJECTIVE: To study the influence of both pH and complexation by hydroxypropyl - β - cyclodextrin (HPCD) on the overall ,solubility of hydroxycamptothecin (HCPT) with particular focus on the equilibrium between its lactone- and carboxylate- form. METHODS: Phase solubility studies at pH values and physiologically acceptable HPCD concentrations were performed, and the amounts of solubilized HCPT quantified by HPLC. The lactone - carboxylate - ratios from the equilibrium were studied. RESULTS: The solubility of HCPT increased with both increasing pH and HPCD concentration. The apparent complexation constant decreased with increasing pH. The lactone- carboxylate equivalence point shifted from a pH value of 6,5, 7.0 and 7.3 with 0%, 10% and 25% HPCD, respectively. Separate complexation constants for the carboxylate - HCPT and lactone- HCPT could thus be derived. CONCLUSION : The solubilizing and stabilizing effects of HPCD on HCPT in aqueous solution were good.
出处 《中国药房》 CAS CSCD 北大核心 2008年第4期269-272,共4页 China Pharmacy
关键词 2-羟丙基-Β-环糊精 羟基喜树碱 内酯环 羧酸盐 稳定 溶解度 2- hydroxypropy1-β-cyclodextrin Hydroxycamptothecin Lactone Carboxylate Stability Solubility
  • 相关文献

参考文献9

  • 1Zhou J J, Liu J, Xu B. Relationship between lactone ring forms of HCPT and their antitumor activities[J ] . Acta Pharmacol Sin, 2001,22(9): 827.
  • 2谷福根,崔福德,高永良.前列腺素E_1与羟丙基-β-环糊精在水溶液中包合作用的研究[J].药学学报,2004,39(9):742-746. 被引量:21
  • 3Irie T, Uekama K. Pharmaceutical applications of cyclodextrins, Ⅲ. Toxicological issues and safety evaluation[J ] .J Pharm Sci , 1997, 86(2):47.
  • 4Higuchi T, Connors KA.Phasc-solubility techniques [J ] .Adv Anal Chem Instr, 1965,4: 117.
  • 5Brewster ME, Simphins JM, Hora MS, et al .The potential use of cyclodextrins in parenteral formulations [J ] . J Parent Sci Tech , 1989,43(5):231.
  • 6Mura P, Faucci MT, Bettinetti GP. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl - β - cyclodextrin[J ] .Eur J Pharm Sci, 2001,13(2) : 187.
  • 7Helm H, Muller BW, Waaler T.Complexation of dihydroergotamine mesylate with cyciodextrin derivatives: Solubility and stability in aqueous solution[J] .Eur J Pharm Sci, 1995,3(3) : 195.
  • 8Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery[J ] . Pharm Res, 1997, 14(6) : 556.
  • 9Loftsson T, Brewster ME, Pharmaceutical applications of cyclodextrins. Ⅰ. Drug solubilization and stabilization[J ] .J Pharm Sci, 1996,85(10) : 1 017.

二级参考文献12

  • 1Kloze J. Relationship between chemical structure and platelet-aggregation activity of prostaglandins [ J ].Biochim Biophys Acta, 1969,187:285 -292.
  • 2Olsson AG, Carbon LA. Clinical, haemodynamic and metabolic effects of intraarterial infusion of prostaglandin E1 in patients with peripherial arterial disease [J]. Adv Prostaglandin Thrombox Res, 1976,1:429 - 432.
  • 3Yang ZH, Chen YQ, Yang GC. Advance in clinical applications of prostaglandin E1 [ J ]. China Pharm Industry (中国药业) , 2001,10(8) :52.
  • 4Hirayama F, Kurihara M, Uekama K. Mechanisms of deceleration by methylated cyclodextrins in dehydration of prostaglandin E2 and the isomerization of prostaglandin A2 in aqueous solution [J]. Chem Pharm Bull, 1986,34(12) :5093 -5101.
  • 5Adachi H, Irie T, Hirayama F, et al. Stabilization of prostaglandin E1 in fatty alcohol propylene glycol ointment by acidic cyclodextrin derivative, O-carboxymethyl-O-ethyl-β-cyclodextrin [ J ] Chem Pharm Bull, 1992,40(6) :1586 - 1591.
  • 6Ding PT, Wu XM. A new pharmaceutical excipient 2-hydroxylpropyl-β-cyclodextrin [ J ]. World PharmacyChemicals,Biochem Pharm Division(国外医药.合成药生化药制剂分册),1996,17(2):107-111.
  • 7Gatti R, Gotti R, Cavrini V, et al. Stability study of prostaglandin E1 (PGE1) in physiological solutions by liquid chromatography ( HPLC ) [ J ]. Int J Pharm,1995,115:113 - 117.
  • 8Higuchi T, Connors KA. Phase solubility techniques [J]. Adv Anal Chem Instrum, 1965,4:117 -212.
  • 9Loukas YL. Evaluation of the methods for the determination of the stability constant of cyclodextrinchlorambucil inclusion complexes [ J ]. J Pharm Biomed Anal, 1997,16:275 - 280.
  • 10Nina SS. The thermodynamic parameters of the formation of a complex between cyclodextrins and hormones [J]. J Chromatogr A, 1996,728:89 - 95.

共引文献20

同被引文献74

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部